Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Immediate Effects of Active Prisms on Reading Automaticity and Motor Control in Young Adults With Developmental Dyslexia

NCT07868367 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-10-01
Last updated
2026-10-09

Condition(s) studied

Developmental Dyslexia

Investigational drug(s) / intervention(s)

Individually Selected Active Prisms.

Individually Selected Active Prisms.: Individually selected active prisms (0.25-3 prism diopters) will be worn during post-intervention assessments by participants with dyslexia to modify tonic muscle distribution. The intervention will take place during one study visit.

Study summary

Developmental dyslexia is associated with persistent difficulties in reading automaticity. AUTO-DYS investigates whether a single, brief intervention using active prisms changes the complexity of nonlinear movement dynamics and reading automaticity in young adults with dyslexia. This single-center, prospective, non-randomized controlled study will enroll 66 adults aged 18-30 years: 33 with developmental dyslexia and 33 typical readers. All participants will undergo reading, postural-control, and working-memory assessments before and after an experimental period during one visit. Only participants with dyslexia will receive individually selected active prisms; typical readers will repeat the assessments without active prisms. The main hypothesis is that modifying tonic muscle distribution with active prisms is associated with increased dynamic complexity and improved reading automaticity in participants with dyslexia.

Eligibility

Sex
ALL
Min age
18 Years
Max age
30 Years
Healthy volunteers
Accepted
Inclusion Criteria: Adults aged 18-30 years with normal or corrected vision. Dyslexia group: documented medical diagnosis of developmental dyslexia and an Alouette-R C index greater than two standard deviations, as specified in the protocol, on the study day. Control group: typical readers with an Alouette-R C index less than two standard deviations, as specified in the protocol, on the study day. Eligibility will be verified by the study physician. Exclusion Criteria: * Optical correction exceeding ±0.75 diopters * known balance or psychiatric disorder * another diagnosed neurodevelopmental disorder in the dyslexia group * any diagnosed neurodevelopmental disorder or proprioceptive dysfunction in the control group * pregnancy * legal guardianship * pathological near-vision Parinaud test (P2) * refusal of consent.

Primary outcome measure(s)

  • Change in Detrended Fluctuation Analysis Alpha Coefficient — Baseline and immediately after the intervention/control period, within the same approximately two-hour visit.
    Change in detrended fluctuation analysis alpha coefficient (α-DFA), reflecting fractal self-similarity and the complexity and adaptability of nonlinear dynamics.
  • Change in High-Frequency Word Reading Effect — Baseline and immediate post-test during one approximately two-hour visit.
    Change in the high-frequency word effect during silent reading, used to assess reading automaticity.

Trial sites (1)

FacilityCityRegionStatus
Université de Lille, Federation for Research in Visual Sciences and Cultures (FR-SCV), Plaine Images, Bâtiment L'Imaginarium Tourcoing France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07868367 on ClinicalTrials.gov ↗ ← All trials in France